Ma Ianuali 22, 2025, ua paʻi ʻo "Nature Medicine" i nā hopena o ka PD-1/CTLA-4 bispecific antibody cadonilimab i hoʻomohala kūʻokoʻa ʻia e Akeso i hui pū ʻia me oxaliplatin a me capecitabine no ka lāʻau lapaʻau mua o ka adenocarcinoma gastric a gastroesophageal junction (G/GEJ) i hiki ʻole ke hoʻopau ʻia ma kahi pae holomua a metastatic paha i loko o kahi noiʻi lapaʻau Phase III (COMPASSION-15/AK104-302).Ua hōʻike waha ʻia nā hopena o ke aʻo ʻana COMPASSION-15 ma ka Hālāwai Makahiki 2024 o ka American Association for Cancer Research (AACR).
He haʻawina pae 3 randomized kēia, makapō pālua, placebo-controlled. ʻO nā maʻi kūpono he mau pākeke me ka adenocarcinoma G/GEJ i mālama ʻole ʻia, hiki ʻole ke ʻoki ʻia, holomua kūloko a metastatic paha. Ua randomized nā maʻi 1:1 e loaʻa iā cadonilimab (10 mg kg−1 i kēlā me kēia 3 pule) a i ʻole placebo me chemotherapy (i kēlā me kēia 3 pule). ʻO ke kumu hope loa ʻo ke ola holoʻokoʻa (OS) i ka heluna kanaka manaʻo e mālama (pae koʻikoʻi hoʻokahi ʻaoʻao, P = 0.025). ʻO nā kumu hope lua i hoʻokomo iā OS i nā maʻi me ka helu maikaʻi PD-L1 i hui pū ʻia ≥5, ke ola ʻole holomua, ka helu pane pahuhopu, ka lōʻihi o ka pane a me ka palekana. Ma ka lā 18 ʻAukake 2023, ua randomized ʻia he 610 mau maʻi mai 75 mau kikowaena haʻawina i cadonilimab (n = 305) a i ʻole placebo (n = 305). Me ka nānā ʻana ma waena o 18.7 mau mahina, ua lōʻihi loa ka OS waena o ka hui cadonilimab (14.1 versus 11.1 mau mahina; lakio pilikia (HR) 0.66; 95% hilinaʻi waena (CI) 0.54–0.81; P < 0.001) ma mua o ka hui placebo. Ua hoʻokō ʻia ka hopena mua. ʻO ke ola ʻana ma waena o ka holomua ʻole he 7.0 mau mahina versus 5.3 mau mahina (HR 0.53, 95% CI 0.44–0.65). ʻO ka OS waena i nā maʻi me ka helu maikaʻi PD-L1 i hui pū ʻia he ≥5 he 15.3 mau mahina versus 10.9 mau mahina (HR 0.58, 95% CI 0.41–0.82). ʻO ka helu pane pahuhopu he 65.2% versus 48.9% me ka lōʻihi o ka pane ʻana ma waena o 8.8 mau mahina versus 4.4 mau mahina. Ua ʻike ʻia nā hanana ʻino e pili ana i ka lāʻau lapaʻau Papa ≥3 ma 65.9% o ka hui cadonilimab a me 53.6% o ka hui placebo, a ʻo ka mea maʻamau ka emi ʻana o ka helu platelet, ka emi ʻana o ka helu neutrophil a me ka anemia. ʻO ka hapa nui o nā hanana ʻino e pili ana i ka pale ʻana he papa 1 a i ʻole 2. ʻAʻohe hōʻailona palekana hou i ʻike ʻia. Ua hoʻomaikaʻi nui ʻo Cadonilimab me ka chemotherapy iā OS me kahi ʻano palekana hiki ke hoʻokele ʻia i nā poʻe maʻi me ka adenocarcinoma G/GEJ holomua.
ʻO ka inikini Cadonilimab kahi lāʻau lapaʻau immunotherapy bi-specific PD-1/CTLA-4 mua loa i hoʻomohala ʻia i loko o ka hale. Ma Iune 29, 2022, ua ʻae ʻia ʻo Cadonilimab e ka NMPA o Kina no ka mālama ʻana i nā maʻi maʻi kanesa cervical relapsed a metastatic paha (R/M CC) i holomua ma luna a ma hope paha o ka chemotherapy platinum-based. I Kepakemapa 2024, ua ʻae ʻia kahi hōʻailona hou no cadonilimab no ka mālama mua ʻana i nā maʻi me ka adenocarcinoma gastric a gastroesophageal junction (G/GEJ) locally advanced unresectable a metastatic paha, i hui pū ʻia me ka fluoropyrimidine a me ka chemotherapy platinum-based. I kēia manawa, ua ʻae ʻia nā noi lāʻau hou no Cadonilimab i hui pū ʻia me ka chemotherapy platinum-based, me ka bevacizumab a i ʻole me ka ʻole, no ka mālama mua ʻana i ka maʻi kanesa cervical mau loa, recurrent, a metastatic paha e ka CDE. Eia kekahi, ke hana ʻia nei me ka pono kahi moʻo o nā haʻawina lapaʻau, me kahi hoʻokolohua pae III no ka adjuvant therapy i nā poʻe maʻi me ka pilikia kiʻekiʻe o ka hoʻi hou ʻana ma hope o ka resection curative o ka hepatocellular carcinoma.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
Email：myimmnet@163.com
Nā Kuhikuhi
https://www.nature.com/articles/s41591-024-03450-4
Ka manawa hoʻouna: Pepeluali-21-2025